Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM
Formycon and Fresenius Kabi receive FDA approval for FYB202/Otulfi™ (ustekinumab-aauz), a biosimilar to Stelara®, for treating Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis. This marks Formycon's third successful FDA approval for a biosimilar, with Fresenius Kabi set to market Otulfi™ in the US by February 22, 2025, under a patent settlement with Johnson & Johnson.
J&J Posts Positive Phase III Results for Carvykti and Darzalex Faspro in Multiple Myeloma Trials
J&J announced positive clinical trial data for its multiple myeloma drugs Carvykti and Darzalex Faspro, showing improved outcomes. Carvykti demonstrated a 45% reduction in death risk and 76% OS rate at 30 months, while Darzalex Faspro improved minimal residual disease-negativity by 60.9%.
Johnson & Johnson's CARVYKTI improves survival in trial
Johnson & Johnson's CARVYKTI cell therapy significantly improved overall survival in Phase III CARTITUDE-4 trial for multiple myeloma patients, reducing mortality risk by 45% compared to standard therapies.
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi announce FDA approval of FYB202/OtulfiTM (ustekinumab-aauz), a biosimilar to Stelara®, for treating Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis. This marks Formycon’s third successful FDA approval for a biosimilar, with Fresenius Kabi set to market OtulfiTM in the US by February 2025.
Johnson & Johnson announces updated results from phase 1b RedirecTT-1 study of Talvey
Johnson & Johnson's RedirecTT-1 study shows high response rates and durable responses with Talvey and Tecvayli bispecific antibody combination in relapsed or refractory multiple myeloma patients, including those with extramedullary disease, with a consistent safety profile. The overall response rate was 79.5%, with a complete response or better rate of 52.3%.
European Commission approves Yuvanci® (Single Tablet
The European Commission approves Yuvanci®, a single tablet combination therapy for PAH, marking the first such option in Europe. This approval is based on the Phase 3 A DUE study, which showed significant reductions in pulmonary vascular resistance compared to individual monotherapies. Yuvanci® addresses the unmet need for simplified PAH treatment regimens, aligning with ESC/ERS guidelines.
Novel combination of TALVEY® (talquetamab) and TECVAYLI® (teclistamab) suggest high response rates and durable responses in relapsed or refractory multiple myeloma patients
Updated RedirecTT-1 study results show high response rates and durable responses with a consistent safety profile for talquetamab and teclistamab combination in relapsed or refractory multiple myeloma patients, presented at the 2024 IMS Annual Meeting.
Related Clinical Trials:
Ultrasound cancer treatment, supported by Li Ka-shing, gains traction in Asia: US expert
Focused ultrasound, backed by Hong Kong tycoon Li Ka-shing, is gaining recognition as a commercially attractive alternative to traditional therapies for diseases like cancer. The growth in treatments, clinical trials, and investments indicates its scaling up, with HistoSonics, a focused ultrasound device maker, attracting significant investments. The Li Ka Shing Foundation has donated devices to the University of Hong Kong and plans further donations to support treatment and training.
Johnson & Johnson announces updated results from Phase 1b RedirecTT-1 study
Johnson & Johnson's Phase 1b RedirecTT-1 study shows high response rates and durable responses with a consistent safety profile for the combination of TALVEY and TECVAYLI in triple-class exposed, relapsed or refractory multiple myeloma patients, including those with extramedullary disease.
© Copyright 2025. All Rights Reserved by MedPath